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Available online 4 April 2016Adverse CNS effects account for a sizeable proportion of all drug attrition cases. These adverse CNS effects areme-
diated predominately by off-target drug activity on neuronal ion-channels, receptors, transporters and enzymes
— altering neuronal function and network communication. In response to these concerns, there is growing sup-
port within the pharmaceutical industry for the requirement to performmore comprehensive CNS safety testing
prior to ﬁrst-in-human trials. Accordingly, CNS safety pharmacology commonly integrates several in vitro assay
methods for screening neuronal targets in order to properly assess therapeutic safety. One essential assaymethod
is the in vitro electrophysiological technique — the ‘gold standard’ ion channel assay. The in vitro electrophysio-
logical method is a useful technique, amenable to a variety of different tissues and cell conﬁgurations, capable
of assessingminute changes in ion channel activity from the level of a single receptor to a complex neuronal net-
work. Recent advances in automated technology have further expanded the usefulness of in vitro electrophysio-
logical methods into the realm of high-throughput, addressing the bottleneck imposed by themanual conduct of
the technique.However, despite a large range of applications,manual and automated in vitro electrophysiological
techniques have had a slow penetrance into the ﬁeld of safety pharmacology. Nevertheless, developments in
throughput capabilities and in vivo applicability have led to a renewed interest in in vitro electrophysiological
techniques that, when complimented by more traditional safety pharmacology methods, often increase the pre-
clinical predictability of potential CNS liabilities.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Electrophysiology
EEG
Central nervous system
In vitro
Seizure
Brain slice models
Receptor proﬁle screening
Memory loss
Animal models1. Introduction
Upon the adoption of the International Conference on
Harmonisation (ICH) S7A guidelines (FDA, 2001), the central nervous
system (CNS)was recognized as a central pillarwithin theﬁeld of safety
pharmacology (Pugsley, Authier, & Curtis, 2008). Testing strategies and
practices aimed at addressing adverse CNS effects represent an impor-
tant aspect to the development of any new chemical entity (NCE)
since they attempt to prevent serious adverse drug reactions (ADR)
from occurring within the clinical setting. Despite this, drug candidates
continue to fail within clinical studies due to adverse CNS effects
(Arrowsmith&Miller, 2013)— increasingpressure tominimize drug at-
trition rates within pharmaceutical development (Hay, Thomas,
Craighead, Economides, & Rosenthal, 2014; Kola & Landis, 2004;
Palmer & Alavijeh, 2012; Pangalos, Schechter, & Hurko, 2007; Waring
et al., 2015). This pressure is further exacerbated by the fact that 10%
of all marketed pharmaceuticals withdrawn between 1960 and 1999
were withdrawn due to adverse CNS effects stemming mostly from
neurologic, psychiatric and abuse liabilities (Fung et al., 2001;. This is an open access article underHamdam et al., 2013). Thus, with an ageing global population and a
growing demand for novel pharmaceutical therapies, the need to ade-
quately assess adverse CNS effects earlier in the drug development is
paramount.
As deﬁned by the ICH S7A, the core battery of CNS safety pharmacol-
ogy studies consists of investigations conducted in accordance with
good laboratory practice (GLP) standards and involve in vivo observa-
tions together with follow-up studies, if appropriate (Fonck, Easter,
Pietras, & Bialecki, 2015; Hamdam et al., 2013). Traditionally, the most
common core battery tests used within CNS safety pharmacology are
behavioral assays such as the Irwin assay (Irwin, 1968) and the func-
tional observational battery (FOB) (Moser, Cheek, & MacPhail, 1995).
These tests rely heavily upon subjective endpoints and require highly
experienced observers to ensure experimental reproducibility (Fonck
et al., 2015). Technological advances such as electroencephalography
(EEG) (Durmuller, Guillaume, Lacroix, Porsolt, &Moser, 2007), conduct-
ed either alone or paired with telemetry (Authier et al., 2014; Kramer &
Kinter, 2003) and/or integrated video systems (Authier et al., 2009),
have afforded safety pharmacologists more quantitative and objective
endpoints with which to assess adverse CNS effects in unstressed
animals. When paired with behavioral assays, EEGs represent a robust
strategy linking clinical manifestations to altered neuronal activity.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to-noise and a lack of regional accuracy (Castagné et al., 2013; Fonck
et al., 2015; Hamdam et al., 2013; Porsolt, Lemaire, Durmuller, & Roux,
2002) preventing complete predictability of results to the clinical set-
ting. Thus, follow-up CNS safety studies are required, and if conducted
at earlier stages of drug development, should help to improve clinical
outcome predictability and ultimately reduce drug attrition rates.
Neuronal-based assays for screening ion-channel targets are rapidly
emerging as key assays implemented early during CNS safety pharma-
cology testing (Bowes et al., 2012; Gonzalez, Oades, Leychkis,
Harootunian, & Negulescu, 1999; Mattheakis & Savchenko, 2001;
Terstappen, 2005; Terstappen, Roncarati, Dunlop, & Peri, 2010; Xu
et al., 2001). Ion-channels are pore-forming, membrane-bound pro-
teins, permeable to speciﬁc ions, which play fundamental roles in
inter- and intracellular communication and neuronal excitability. As
such, ion-channels have been subjected to rigorous research investiga-
tions into a very broad range of important therapeutic areas since nu-
merous disease states are associated with their dysfunction (Babcock
& Li, 2013; Kaczorowski, McManus, Priest, & Garcia, 2008; Kullmann,
2010). Adding to this point, roughly 15% of the most successfully
marketed pharmaceutical drugs target ion-channels (Overington,
Al-Lazikani, & Hopkins, 2006) with a market value in excess of $10
billion (USD) (Terstappen et al., 2010). However, ion-channels also
serve as highly promiscuous targets for small molecules and thus con-
tribute to ADRs and off-target interactions (Lounkine et al., 2012).
Some of the most notorious off-target interactions are associated
with ion-channels such as the human ether-à-go-go-related gene potas-
sium channel (hERG, also known as KCNH2), voltage-gated sodium
channel (SCN5A), γ-aminobutyric acid type-A receptor (GABAAR)
and N-methyl-D-aspartate receptor (NMDAR). Accordingly, these ion-
channels have been suggested to be screened in the early assessment
of the potential hazard of a NCE (Bowes et al., 2012).
Some of the most common neuronal-based assays for screening
drug-induced effects on ion-channel functionality rely on exploiting
key aspects of ion-channel activity such as ligand binding, ion ﬂux
or the resultant modulation of neuronal membrane potential (see
Table 1). Of these assays, the ‘gold standard’ for assessing ion-channel
function is the patch-clamp electrophysiological technique (Hamill,
Marty, Neher, Sakmann, & Sigworth, 1981; Neher & Sakmann, 1976).
Patch-clamp electrophysiology is a technique inwhich one canmeasure
the biophysical (e.g., activation anddecay kinetics) and pharmacological
properties of ion-channels on millisecond timescales with up to single
channel resolution. Thus, this technique is capable of generating precise,
high quality data. The advent of automated robotic patch-clamp sys-
tems in recent years has made patch-clamp electrophysiology a high-
through technique able to meet the demandwithin the pharmaceuticalTable 1
Common ion channel assays.
Method Assay Type Throughput
Radioligand binding assay Biochemical High
Radioactive ﬂux assays Functional Medium–high
Nonradioactive ﬂux assays
Based on atomic absorption spectrometry Functional High
Based on ion-speciﬁc ﬂuorescence dyes Functional Medium–high
Fluorescence assays
Based on voltage-sensing dyes Functional Medium–high
Fluorescence resonance energy transfer (FRET) Functional High
Electrophysiology
Manual patch-clamp Functional Low
Automated robotic patch-clamp systems Functional Medium–high
Planar array based recording interfaces Functional High
Multielectrode array Functional Medium–high
Oocyte recording techniques (manual and automated) Functional Low–mediumindustry (Dunlop, Bowlby, Peri, Vasilyev, & Arias, 2008; Terstappen
et al., 2010). Together, manual and automated patch-clamp systems
represent only a small window into theworld of in vitro electrophysiol-
ogy where various other techniques and platforms are also available
for use; however each with their own merits and limitations. Due to
the robustness and utility of the method, in vitro electrophysiological
techniques are beginning to emerge as important ﬁxtures in safety
pharmacology. This is, in part, due to the growing support for the
requirement to perform more comprehensive CNS safety testing prior
to clinical studies (Lindgren et al., 2008; Valentin & Hammond, 2008).
As such, this review will brieﬂy highlight common electrophysiological
methods with the greatest translational potential for safety pharmacol-
ogy aswell as provide a brief look into the emerging role of in vitro elec-
trophysiology within CNS safety pharmacology.
2. In vitro electrophysiological approaches
Despite the embracement of in vivo electrophysiological approaches
early in CNS safety investigations (e.g., EEG), in vitro electrophysiology
methods have often been regulated to follow up CNS studies in late
phase testing. This is surprising since EEGs record the ensemble electri-
cal activity of the brain and thus itwould be useful to also providemech-
anistic information related to drug-induced modulation at the level of
the individual neuron, receptor or ion channel early in safety testing.
As an example, studies on the hERG channel have shown that subtle
blockade in channel activity, which may contribute to long QT interval
and Torsade de pointes, may go unnoticed during electrocardiograph
evaluation (Moller & Witchel, 2011; Viskin et al., 2005). Accordingly,
the ICH S7B guidelines emphasize that in vitro electrophysiology studies
must play a key role in addressing potential hERG channel interactions
(FDA, 2005). A similar approach has not yet been mandated for CNS
ion-channels, but a systematic in vitro electrophysiological exploration
of neuronal ion channels are included by a number of large pharmaceu-
tical companies for the characterization of a NCE.
In vitro electrophysiological techniques in CNS studies exploit ionic
conductance of ion-channels and transient modulation of the mem-
brane potential of a neuron. If the membrane potential becomes sufﬁ-
ciently depolarized, an action potential will trigger. Many in vitro
electrophysiology techniques have been developed to detect and ma-
nipulate ion-channel function and/or action potential generation. The
applicability of each technique is dependent upon numerous factors in-
cluding, but not limited to, the biophysiological properties of the record-
ed cell, the tissue preparation, the use of current- and/or voltage-clamp,
manipulation of the intra- and/or extracellularmilieu, the detection of a
single channel or ensemble responses, the study of responses at the
channel, neuron or network level, and intra- vs. extracellular recordings.Temporal resolution
Comments
N/A Does not provide functional data
Seconds–minutes Use of radioactive isotopes
Seconds–minutes K+ and nonselective cation channels
Seconds Ca2+and nonselective cation channels
Seconds–minutes Useful in cell lines that pass little or no Ca2+
Sub-second Indirect measurement of channel activity; ratiometric
Sub-millisecond Sensitive to single channel resolution
Millisecond 10-fold higher throughput than manual patch-clamp
Millisecond
Up to 1000-fold higher throughput than manual patch-clamp
Millisecond Neuronal population responses
Millisecond High heterologous protein expression within a short period
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applications, a comprehensive review of all electrophysiology methods
is beyond the scope of this review. This review will instead highlight
common in vitro electrophysiological techniques that hold the greatest
translational potential for CNS safety pharmacology testing and those
which are currently employed within the ﬁeld of safety pharmacology.
2.1. Patch-clamp techniques
The most commonly employed in vitro electrophysiological tech-
nique is the patch-clamp method. This method requires the initial
formation of a giga-ohm (GΩ) seal between the plasma membrane
and the blunt tip (0.5–2 μmdiameter) of a heat-polished glass or quartz
micropipette (electrode) (Hamill et al., 1981; Sigworth & Neher, 1980).
This ‘cell-attached’ conﬁguration is a stable non-invasive technique
from which all other patch-clamp conﬁgurations derive (Fig. 1A).
This conﬁguration maintains the integrity of the plasma membrane
(i.e., themembrane seal is not ruptured) preventing the pipette solution
from dialyzing into the cell. However, this lack of seal rupture conse-
quently restricts electrical access to the cell interior resulting in an in-
ability to control the membrane potential of the cell. Consequently,
the cell-attached conﬁguration allows only control of the patch mem-
brane potential relative to the cell’s resting potential. Therefore, by con-
trolling either the magnitude of the seal resistance (loose seal vs. tight
seal) and/or whether the recording electrode is current- vs. voltage-
clamped, the cell-attached conﬁguration can be used to measure single
channel currents, spontaneous neuronal cell ﬁring and synaptic poten-
tials as well as evoked action potentials within the cell.
To increase electrical access to the cell interior, two methods can
be employed. First, the internal pipette solution can bemade to contain
antibiotic or antifungal agents (e.g., nystatin, gramicidin, amphotericin-
B). These agents form small, monovalent ion-permeable pores thatFig. 1.Common in vitro electrophysiologicalmethods. A) The cell-attached patch-clampmethod
The perforated patch, outside-out and inside-out conﬁgurations are not commonly used in CNS
are represented by blue and orange, respectively. B) A representation of the impalement techn
cartoon illustrating a section of a multielectrode array with dissociated neurons cultured direc‘perforate’ (Fig. 1A) the membrane allowing electrical assess to the en-
tire cell. Importantly, these pores do not allow passage of proteins
thus ensuring that the intracellular milieu remains intact preserving in-
tracellular signaling pathways (Horn &Marty, 1988). However, this per-
forated patch technique suffers from several limitations including higher
electrical noise, loss of single channel resolution and patch instability.
Additionally, the perforation process is associated with considerable
time requirements (Sarantopoulos, 2007). Together, these concerns
have dissuaded safety pharmacologists attempting to elucidate phar-
macological effects, and hence drug safety proﬁles of novel NCEs on
neuronal ion channels, fromwidely using this technique. An alternative
approach to the perforated patch technique is to apply a strong suction,
or brief voltage transient, after giga-seal formation in an attempt to rup-
ture the plasma membrane. Upon rupture, a low-resistance electrical
and physical continuity is established between the pipette and the cell
interior known as the whole-cell conﬁguration (Fig. 1A). Accordingly,
this conﬁguration permits direct measurements of the cell’s membrane
potential (via current-clamp) and its manipulation (via voltage-clamp).
Due to the physical continuity between the cell interior and the pipette
solution, the cytosolic contents can be reasonably controlled. Further-
more, unlike the perforated patch, pharmacological or ionic manipula-
tions of both the intracellular and extracellular environment can lead
to the isolation of individual ion-currents. However, this physical conti-
nuity between the pipette lumen and cytosol may also dialyze out and/
or alter the activity of endogenous secondmessenger systems. Thus, it is
critical to assess current ‘rundown’ of the system and cells within
whole-cell CNS studies.
‘Cell-free’ variations of patch-clamp techniques also exist. For in-
stance, upon giga-seal formation, the electrode can be gently retracted
pulling the membrane patch into the bath solution. This arrangement,
known as the inside-out conﬁguration (Fig. 1A), enables the complete
manipulation of the cytoplasmic face of the plasma membrane via theis a stable non-invasive technique fromwhich all other patch-clamp conﬁgurations derive.
safety pharmacology studies. To show potential dialysis, the pipette lumen and cytoplasm
ique known as ‘Two electrode voltage-clamp’ performed on a Xenopus laevis oocyte. C) A
tly over the electrodes.
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tion. As a result, inside-out patches extend the utility of single channel
recordings through the ability to manipulate the immediate environ-
ment of the inner membrane face. Unfortunately, this arrangement suf-
fers from the loss of intracellular signaling pathways acting on the ion-
channels upon patch excision; a particularly important consideration
due to altered channel activity (Covarrubias & Steinbach, 1990;
Trautmann & Siegelbaum, 1983). Conversely, an outside-out patch
(Fig. 1A) also requires the gentle retraction of the patch electrode
from thewhole-cell conﬁguration. However, in this situation the pipette
retraction forces the plasmamembrane surrounding the electrode tip to
detach from the cell and reseal forming a cell-independent patchwhose
extracellularmembrane is facing the bathing solution. As a result, an ex-
perimenter has complete control over the intracellular environment
(albeit without endogenous signaling pathways) and can rapidly ex-
change different external physiological or pharmacologic drugs over
the same patch. This rapid external solution exchange enables the ac-
quisition of concentration-response curves within a single patch up to
single ion-channel resolution.
2.1.1. Manual vs. automated patch-clamp techniques
The manual patch-clamp is considered the ‘gold standard’ for con-
duct of in vitro electrophysiology studies due to its versatility and
high-quality data production. Unsurprisingly, it is widely employed
throughout the academic arena where highly trained personnel are ca-
pable of producing around 10 data points/day (Wood, Williams, &
Waldron, 2004). However, when compared to other ion-channel assays
(e.g., ion- or voltage-sensitive ﬂuorescence-based assays, binding assays
or ion ﬂux measurements), manual patch-clamp methods yield rela-
tively low throughput (Gonzalez et al., 1999). Likewise, the require-
ments for high technical expertise and high maintenance costs have
limited the expansion of this technique into aspects of safety pharma-
cology beyond cardiac evaluation. Thus, given the drivewithin the phar-
maceutical industry to develop new, higher throughput screens, several
automated patch-clamp systems have been developed which simplify
the patching procedure and generate data in an inexpensive, reproduc-
ible and high throughput manner (Dunlop, et al., 2008;; Terstappen,
2005; Terstappen et al., 2010; Yajuan, Xin, & Zhiyuan, 2012).
Automated patch-clamp systems utilized conventional glass
micropipettes (e.g., Apatchi-I Sophion Bioscience), FlyScreen (Flyion
GmbH), AutoPatch (Xention Discovery Limited) and Dynaﬂow HT
(Cellectricon)) or micro-fabricated planar electrode-based (patch-on-
a-chip) technologies for patching either mammalian cells (e.g., Qpatch
(Sophion, Biosciences), NPC-16 Patchliner, SyncroPatch 96 and Port-a-
Patch (Nanion Technologies GmbH), CytoPatch (Cytocentrics CCS),
IonWorks (IonWorks HT and IonWorks Quatto; Molecular Devices),
IonFlux (Fluxion Biosciences Inc) and PatchXpress (Molecular Devices))
or Xenopus laevis oocytes (e.g., OpusXpress (Molecular Devices) and
Roboocyte (IonGate)) (Dunlop et al., 2008; Terstappen, 2005;
Terstappen et al., 2010; Wood et al., 2004; Xu et al., 2001; Yajuan
et al., 2012). In practice these automated systems function by detecting
ensemble responses in a whole-cell or perforated-patch recording,
which is typically achieved by one of two methods: (i) directing a
glass micropipette blindly, or through imaging, towards a cell until a
giga-seal is achieved (or impaled in the case of oocytes; see below) or
(ii) allowing cells to drift, or culturing cells onto a planar surface
possessing micron-size holes from which loose or tight seal formation
can occur (Py et al., 2011; Wood et al., 2004; Yajuan et al., 2012).
When compared to manual patch-clamp techniques, automated sys-
tems signiﬁcantly increase throughput by a factor of ten (e.g., robotic
glass pipette technologies) to upwards of 1000-fold (e.g., planar
electrode-based technologies) (Terstappen, 2005) generating greater
than 10,000 data points/day (Fertig & Farre, 2010) (See Table 1).
Despite this high throughput success, current automated patch-
clamp technologies lack the versatility and quality compared tomanual
patch-clamp. For instance, many automated systems are restricted tothe whole-cell conﬁguration thus limiting their data acquisition to en-
semble responses — precluding single channel measurements. Several
systems lack the ability for ultra-rapid solution exchange (i.e., 1 ms;
on par with synaptic vesicular release) or solution washout which
may underestimate or inaccurately measure the biophysical properties
(e.g., activation, deactivation and desensitization kinetics) of a given re-
sponse. The requirement of some automated platforms for speciﬁc cell
lines, or cell suspensions, precludes the usage of intact tissue prepara-
tions thus restricting the assessment of neuronal network dynamics
(Yajuan et al., 2012). Moreover, many automated systems sacriﬁce
data quality for data volume by tolerating low resistance patches (MΩ
vs. GΩ seals) and high leak currents (Fertig & Farre, 2010; Yajuan
et al., 2012). Taken together, these limitations serve as ever-present
hurdles for automated patch-clamp systems leading to the continued
importance, validity and viability of themanual patch-clamp technique.
2.2. Impalement techniques
For large cells (e.g., Xenopus laevis oocytes), voltage-clamping the
membrane in the whole-cell patch-clamp technique is very difﬁcult.
This is attributable to the large current produced within these cells
that contributes to a signiﬁcant voltage drop across the recording elec-
trode which cannot be acceptability compensated. Consequently, im-
palement techniques have been developed which forcibly penetrate
the membrane of large cells with sharp micropipettes (i.e., in which
tip resistances are tens or hundreds ofMΩ). For example, themost com-
monly employed impalement technique is two-electrode voltage clamp
(TEVC; Fig. 1B). In this technique, two electrodes penetrate the mem-
brane where one acts as a dedicated membrane potential sensor (volt-
age-electrode) and the other as a current injector (current-electrode).
Accordingly, the membrane is voltage clamped by a constant injection
(or removal) of current through the current-electrode. The tips of the
sharp electrodes are comparatively smaller to those used in the patch-
clamp method enabling TEVC to measure the potential inside the cell
with minimal disruption to the cytosolic ionic composition. Xenopus
oocytes are also commonly used during TEVC since their large size
permits impalement by multiple microelectrodes. Together with their
relative lack of endogenous ion-channels and their excellent ability for
high-ﬁdelity homologous protein expression, Xenopus oocytes repre-
sent a popular ion-channel recording and drug screening system (Xu
et al., 2001).
Automated TEVC systems are commercially available allowing for
recordings from multiple oocytes either in a serial (e.g., Roboocyte
(Multi Channel Systems)) or parallel fashion (e.g., OpusXpress (Molecu-
lar Devices)) (Terstappen, 2005; Wood et al., 2004; Yajuan et al., 2012).
Furthermore, although their size precludes whole-cell patch-clamp, oo-
cytes are amenable to the cell-attached patch-clampmethod (as well as
the inside- and outside-out conﬁgurations) and, as such, can be record-
ed from a planar electrode arrays (Klemic, Klemic, Reed, & Sigworth,
2002;Wood et al., 2004). However, development of automated systems
for oocyte recordings has severely lagged behind their mammalian
cell counterpart (Yajuan et al., 2012) for several reasons. First, due to
their non-mammalian nature, oocytes may promote improper post-
translational modiﬁcations (Wood et al., 2004). Second, lipophilic
drugs tend to accumulate in the egg yolk of oocytes resulting in the gen-
eration of markedly different half maximal inhibitory concentration
(IC50) values between TEVC and patched mammalian cells (Wood
et al., 2004; Xu et al., 2001). Third, oocytes are affected by seasonal var-
iation (Xu et al., 2001) which may diminish data quality or throughput.
Forth andﬁnally, oocytes possess accessory follicular cells and a vitelline
membrane which must be removed through digestive treatments be-
fore they can be effectively used for electrophysiology (Methfessel
et al., 1986). As a result of these limitations, oocyte use is primarily re-
stricted to academic or possibly investigative mechanistic studies and
is not commonly utilized in drug safety pharmacology assessments of
NCEs.
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One of the principle limitations of both the patch-clamp and impale-
ment techniques is that they are intracellular recording systems and, as
such, are limited to assessment of individual neurons. Hence, these sys-
tems preclude the accurate assessment of neuronal circuit dynamics.
Although paired-recordings and ﬁeld stimulations can elucidate the
connective patterns between some neurons in the patch-clamp tech-
nique, these recordings are still limited to only a few neurons at a
time. Furthermore, sharp- and patch microelectrodes are sensitive to
mechanical and biophysical instabilities which may dramatically inﬂu-
ence the duration of intracellular recording sessions. Thus, extracellular
recordings have been developed to serve as a non-invasive, long-term,
multi-cell method aimed at studying neuronal circuit connectivity,
physiology and pathology (Spira & Hai, 2013). Extracellular recording
techniques insert electrodes into tissue which, depending on the posi-
tioning and tip size, measure (with sub-millisecond time resolution)
the extracellular ﬁeld potential generated by an action potential dis-
charge from either a single neuron (single-unit recording) or neuronal
population (multi-unit recording). Therefore, extracellular recordings
can be used to understand neuronal communication, information
encoding, propagation, processing and computation of neuronal circuits
(Obien, Deligkaris, Bullmann, Bakkum, & Frey, 2014).
One of the more notable methods of extracellular recordings is the
use of substrate-integrated microelectrode arrays (MEA; Fig. 1C)
(Obien et al., 2014). MEAs addresses neural network dynamics by sens-
ing extracellular ﬁeld potentials and have been adapted to function in a
high throughput capacity for several tissue preparations such as prima-
ry cell cultures, stem-cell-derived neuronal cultures (Illes, Fleischer,
Siebler, Hartung, & Dihne, 2007), mixed organotypic slice cultures
(Berdichevsky, Sabolek, Levine, Staley, & Yarmush, 2009) and acute
brain slices Fonck et al., 2015; Obien et al., 2014). Several commercial
enterprises (e.g., AlphaMED; Axion-Biosystems; Ayanda; Multi Channel
Systems) currently offer marketed MEAs which typically consist of a
grid of upwards to several hundred integrated electrodeswhich concur-
rently record the passive and stimulated electrophysiological activity of
a tissue Obien et al., 2014; Py et al., 2011). Upon analysis of these record-
ings, a precise understanding of the focus and spread of electrical activ-
ity across the tissue preparation can be established. The utility of these
arrays can be further increased by combining multiple arrays so that
over 10,000 electrodes can be utilized and up to 200 compounds
assessed per day (Johnstone et al., 2010; Py et al., 2011). MEAs also per-
mit culturing of neurons directly onto the electrode arrays which may
enable a continued use of MEAs for several days – a useful application
for investigations of chronic drug exposure (Johnstone et al., 2010;
Spira & Hai, 2013). Recent advances in nanotechnology have also
begun to improve the signal-to-noise ratio for MEA recordings (Py
et al., 2011; Spira & Hai, 2013), a persistent limitation for MEAs due to
the low amplitude signals (e.g., 10 - 500μV) generated by ﬁeld potentials
(Obien et al., 2014; Py et al., 2011).
3. Common in vitro CNS tissue models for electrophysiology
Safety pharmacology aims to predict the clinical risk proﬁle of a po-
tential new drug prior to ﬁrst-in-human studies. Accordingly, it is im-
perative to select the most appropriate tissue and animal model for
testing during electrophysiological investigations to ensure adequate
predictability can be attained. This is a particularly important issue in
CNS safety pharmacology since interspecies differences in ion-channel
expression, drug metabolism and neuroanatomy can result in the man-
ifestation of different drug effects between preclinical species and
humans (Atack et al., 2011). To address these challenges, in vitro elec-
trophysiology methods are amenable to a variety of tissue preparations
suitable for studying adverse CNS effects. Isolated, in vitrowhole brain
preparations have been used in electrophysiological experiments
(e.g., Gnatkovsky, Librizzi, Trombin, and de Curtis (2008)) but are ratherrestrictive in terms of access to, and visibility of, the internal brain struc-
tures – limiting the use of several patch-clamp conﬁgurations. Accord-
ingly, alternative preparations have been developed which provide a
simpliﬁedmodel of the in vivo conditionwhose reduced complexity en-
ables accurate and reliablemethods for studying key neuronal processes
on both the cellular andmolecular level (Bal-Price & Hogberg, 2014). At
the same time, some tissue preparations suffer several concessions due
to their simplicity, limiting direct in vivo comparisons. Therefore,
the process of tissue selection must be driven by the question being ad-
dressed, the cost, training and expertise required to successfully estab-
lish, validate and apply the model and the speciﬁc target endpoints.
3.1. Expression systems and immortalized cell lines
The most rudimentary in vitro electrophysiological models for CNS
investigations are heterologous and recombinant expression systems
which are cells/cell lines that can be maintained in culture for an ex-
tended period of time. The cells/cell lines typically used as heterologous
(e.g., Xenopus oocytes; (Methfessel et al., 1986)) or recombinant expres-
sion systems (e.g., human embryonic kidney 293 (HEK-293) cells,
Chinese hamster ovary (CHO) cells; (Khan, 2013; Thomas & Smart,
2005)) are easily maintained, amenable tomanual and automated elec-
trophysiological techniques and faithfully express high levels of desired
protein within a short period of time. As such, these systems have been
used extensively to evaluate the pharmacological properties and
structure-function relationships of multiple CNS ion-channels. Howev-
er, despite their simplicity and ubiquitous use, these cells lack many of
the complexities associated with neuronal function within the intact
brain (e.g., network associations, glial interactions, and developmental
regulation) — a disadvantage when attempting to predict CNS safety.
Furthermore, these cells are of a non-neuronal origin and thus lack the
same sophisticated level of cellular architecture, sub-cellular organiza-
tion or biochemistry associated with native neuronal preparations
(Thomas & Smart, 2005).
Early efforts to address these non-neuronal concerns focused on
neuronal cells derived from mouse neuroblastoma C-1300 tumor (e.g.,
N1E-115) (Spector, 1981) or the human SH-SY5Y neuroblastoma cell
line (Puchacz, Buisson, Bertrand, & Lukas, 1994; Seward, Henderson, &
Sadée, 1989; Toselli, Masetto, Rossi, & Taglietti, 1991). However, subse-
quent advances in molecular biology enable the use of neural stem cells
(NSCs). NSCs are uncommitted cells with self-renewal potential and the
ability to differentiate into cells of all neural lineages (Bal-Price &
Hogberg, 2014;Weiss et al., 1996). These cells can be derived from sev-
eral sources such as pluripotent embryonic stem cells isolated from the
blastocyst, human umbilical cord blood, induced pluripotent stem cells
and multipotent somatic progenitors derived from several tissues in-
cluding the CNS (Bal-Price & Hogberg, 2014). NSCs derivation has oc-
curred with both non-human (e.g., mice, rats) and human tissue, the
latter of which enables direct extrapolation to the human situation
(Bal-Price & Hogberg, 2014). Electrophysiologically, these cells possess
Na+, K+ and Ca2+ currents in accordance with the known patterns
described for their in vivo neuronal counterparts, even at early
stages of differentiation (Bain, Kitchens, Yao, Huettner, & Gottlieb,
1995; Cho et al., 2002; Jelitai, Anderova, Chvatal, & Madarasz, 2007;
Risner-Janiczek, Ungless, & Li, 2011; Song, Stevens, & Gage, 2002).
Furthermore, these cells are also capable of forming rudimentary, yet
functional, glutamatergic and GABAergic synapses in culture (Toda,
Takahashi, Mizoguchi, Koyano, & Hashimoto, 2000). Nevertheless, de-
spite these beneﬁts, several sources of NSCs (e.g., embryonic or fetal
neural stem cells) are limited in use due to ethical concerns. Additional-
ly, those obtained from adults offer limited neural lineage potential and
senesce after only a few passages (Jakel, Schneider, & Svendsen, 2004).
Moreover, NSC cultures may possess mixtures of both undifferentiated
and differentiated neurons, for which some neurons are developmen-
tally immature, and thus hinder extrapolation of data to the adult
in vivo condition (Jakel et al., 2004).
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Increasing in complexity, dissociated neuronal primary cultures rep-
resent another common tissue preparation used in electrophysiological
investigations (Harry et al., 1998). These cultures are mechanically and
enzymatically dissociated from various brain regions (e.g., hippocam-
pus, cortex, cerebellum, striatum, midbrain, superior cervical ganglion,
etc.) and consist of either one predominant neuronal cell type, a co-
mixture of different neuronal populations or mixed neuronal–glial cul-
tures (Bal-Price & Hogberg, 2014; Harry et al., 1998). Dissociated neu-
rons and astrocytes retain much of their functional capacity in vitro
enabling these preparations to address many important processes
observed in the in vivo condition such as network dynamics and
neuronal-glial interactions (Bal-Price & Hogberg, 2014). However, the
success of dissociated cultures is dependent upon speciﬁc requirements
dictated by the neuron being cultured (Shahar, de Vellis, Vernadakis, &
Haber, 1989). If these conditions are not met, isolated neurons may de-
velop altered morphology and functions modifying their response to
drugs when compared to the in vivo situation (Bal-Price & Hogberg,
2014; Costa, 1998). For instance, the age of the donor at harvest can
largely inﬂuence the success of a culture (Harry et al., 1998) partly
due to altered receptor expression between embryonic tissue and tissue
isolated frommore mature neurons (Lin et al., 2002). Furthermore, dis-
sociated neurons cannot be maintained in culture for extended periods
of time (Humpel, 2015) and thus are required to be freshly isolated on a
regular basis.
3.3. Three-dimensional (3D) neuronal models
The 3D neuronal model represents the next level of complexity for
CNS in vitro models. Like the two-dimensional (2D) preparations
discussed above, 3Dbrain cell cultures can consist of a co-mixture of dif-
ferent neuronal and non-neuronal populations obtained from different
sources such as cell lines (Labour, et al., 2012), dissociated neuronal pri-
mary cells (vanVliet et al., 2008) and stem cells (Giobbe et al., 2012). In-
terestingly, instead of being cultured in a traditional planar monolayer,
3D brain cultures are created up to 10 cell diameters thick within reag-
gregate or spherical cultures (i.e., spheroids), hydrogel/scaffold cultures
or rotary bioreactor cultures with cell aggregates or microcarriers
(Lancaster & Knoblich, 2014; LaPlaca, Vernekar, Shoemaker, & Cullen,
2010).When grown in a 3D environment, neural cells demonstrate bet-
ter survivability and behave differently when compared to traditional
2D-models due in large part to the closer physiological similarity to
the in vivo condition of 3D-models (Fawcett, Housden, Smith-Thomas,
& Meyer, 1989). As such, these models promote better development
of native voltage-gated ion-channel functionality, resting membrane
potentials, intracellular Ca2+ dynamics, Na+/H+ exchange, enhanced
neurogenesis and differentiation, synapse formation, neuronal mobility
and axon myelination (Lancaster & Knoblich, 2014; Lancaster et al.,
2013; LaPlaca et al., 2010; van Vliet et al., 2007). Importantly, these cul-
tures are also compatible with various intracellular and extracellular
(including MEAs) electrophysiological techniques (Huval et al., 2015;
van Vliet et al., 2007); increasing their potential value over traditional
2D-models for safety testing. However, cells residing within the center
of the 3D culture may experience greater levels of oxygen and nutrient
deprivation due to diffusional transport limitations. Accordingly, 3D-
models may suffer from culture-dependent alterations in gene expres-
sion, cell proliferation, viability, productivity and product quality not
typically observed with 2D-models (LaPlaca et al., 2010).
3.4. Brain slice models
Brain slice models (e.g., acute and organotypic slice cultures) repre-
sent the most accurate in vitro electrophysiology preparation of the
in vivo CNS situation since they most closely retain the in vivo-like ste-
reotypic and temporal organization and structural integrity of neuronalmicrocircuits (Gibb & Edwards, 1994). One of the most commonly used
brain slice models in neuroscience is the acute brain slice (Colbert,
2006; Luhmann & Kilb, 2012). Acute brain slices are typically ≤ 450
μm thick and permit easy access to visually identiﬁable neurons and
their dendritic and axonal compartments (Cho, Wood, & Bowlby,
2007). As such, brain slice models enable the application of virtually
all intra- and extracellular electrophysiological techniques in a near
in vivo situation, rapidly after euthanasia. Interestingly, these brain
slices can be harvested from a donor of any age permitting drug safety
assessments on neuronal activity and network processes at any devel-
opmental stage (Humpel, 2015). Unfortunately, factors such as slicing-
induced cell damage, excitotoxicity, the lack of oxygen/glucose supply
to neurons deep within the tissue and bacterial contamination, among
others, limit the lifespan of acute brain slices to roughly 6 – 12 hours
(Buskila et al., 2014; Fukuda et al., 1995).
Organotypic slice cultures – an extension of the acute brain slice
method – are capable of maintaining a brain slice in culture, on a stable
substratum, over prolonged periods of time (e.g., ≥seven days)
(Gahwiler, Capogna, Debanne, McKinney, & Thompson, 1997). This
prolonged period in culture enables the re-establishment of long-
distance connections, severed through the slicing procedure, to an
in vivo-like connection pattern (Gahwiler et al., 1997; Humpel, 2015).
However, unlike the acute brain slice which retains its relative shape
and thickness, organotypic slice cultures ﬂatten into a 3D structure ap-
proximately 3–4 cells thick. Nevertheless, this ﬂattened structure re-
tains the characteristic cytoarchitecture of neurons and glial cells as
well as the anatomical structure of the tissue of origin (Gahwiler et al.,
1997; Humpel, 2015). Notably, unlike acute brain slices, age is very im-
portant for organotypic slice cultures as it is well known that tissue ob-
tained from embryonic or young (i.e. ≤postnatal day 11) donors possess
greater survivability (Humpel, 2015). Remarkably, organotypic cultures
generally show in vitro maturation with synapse development and
spine morphology (Collin, Miyaguchi, & Segal, 1997; Gerﬁn-Moser,
Grogg, Rietschin, Thompson, & Streit, 1995), protein expression (Bahr
et al., 1995) and electrophysiological properties maturing in a pattern
comparable to the in vivo situation (Gahwiler et al., 1997; Humpel,
2015).
3.5. Animal model considerations
The selection of an animalmodel is an important consideration since
there are obvious interspecies differences (i.e., mammalian vs. non-
mammalian) that may promote improper translation of animal data to
the human condition (Lynch, 2009). Furthermore, intra-species differ-
ences (e.g., age and sex of an animal) must also be considered when
selecting the appropriate animal model. In vitro electrophysiological
studies can be conducted using tissue from a variety of animal species
(e.g., Xenopus oocytes, rabbit, rodent, zebraﬁsh and non-human pri-
mate) if human equivalents (e.g., cell lines) are deemed inadequate. Of
these animalmodels, the primary experimental species used for CNS in-
vestigations are rodents, namely mice and rats (Manger et al., 2008).
The development of transgenic mouse models has rapidly increased
the utility of rodent models in CNS research providing a useful model
for a variety of human neurological disorders (e.g., Alzheimer’s disease,
amyotrophic lateral sclerosis, epilepsy) (Harper, 2010). These mutated
mouse models enable the study of pharmacological drug effects in var-
ious disorders. Transgenic, humanized mice models have also shown
good preclinical screening and safety testing potential as they express
the exact protein observed in the human situation (Harper, 2010). Not-
withstanding the fact rodent models have become an invaluable tool to
study neurologic disease, they are nevertheless limited in their ability to
recapitulate the full phenotype of any human disorder and disease
(Lynch, 2009).
One consideration for the limited applicability of rodent models to
humans are the anatomical andmorphological differences observed be-
tween the rodent and human brain (Preuss, 2000). The use of rodent
Table 2
Recommended targets expressed within the CNS for receptor proﬁle safety assessments.a
Class Target Roles within CNS function
G-protein coupled receptors Adenosine receptor A2A receptor Sleep–wake cycle, motor function, cognition
α1A-adrenergic receptor Learning and memory, addition, nociception
α2A-adrenergic receptor Improve working memory, attention, nociception
Cannabinoid receptor type 1 CB1 Nociception, mood, memory, appetite
Dopamine receptor D1 Reward mechanism, addition, memory
Dopamine receptor D2 Reward mechanism, addition, memory, schizophrenia
δ-opioid receptor Nociception, mood, learning
κ-opioid receptor Nociception, drug abuse, addition
μ-opioid receptor Nociception, drug abuse, addition
Muscarinic acetylcholine receptor M1 Arousal, attention, learning and memory
5-HT1A receptor Motor function, mood and emotion, cognition
5-HT1B receptor Addiction, aggression, motor function
5-HT2A receptor Learning and memory, cognition
Ion channels nAChR; α4-subunit Addiction, nociception
GABAAR; α1-subunit BZD site
Sedation, addiction, amnesia
NMDAR; GluN1-subunit Learning and memory
Enzymes
Monoamine oxidase A
Depression
Phosphodiesterase 4D Learning and memory, depression
Transporters Dopamine transporter Attention deﬁcit hyperactivity disorder, schizophrenia
Noradrenaline transporter Mood, addiction, appetite
Serotonin transporter Anxiety, mood, anti-depressant
5-HT, 5-hydroxytryptamine (serotonin) receptor; nAChR, nicotinic acetylcholine receptor; BZD, benzodiazepine; CNS: central nervous system; GABAAR,γ-aminobutyric acid type A recep-
tor; NMDAR, N-methyl-d-aspartate receptor.
a CNS targets within the table were initially identiﬁed within Bowes et al. (2012).
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tion associatedwith the neuroanatomyof higher ordermammalian spe-
cies. Tominimize these concessions, the use of higher ordermammalian
species within in vitro electrophysiology studies may be considered in
the context of tissue slice models where the comparative value of non-
human primate brain slices, for example, can serve to address drug safe-
ty in neuronal circuits with close anatomical and evolutionary ties to
humans (Passingham, 2009; Preuss, 2000). However the use of higher
order mammalian species, particularly nonhuman primates, may not
always be feasible owing to ethical and logistical considerations.
4. Emerging models used in CNS safety pharmacology studies
Drug development is a rather expensive and lengthy endeavor with
recent estimates placing the cost for new drug development at $2.6
billion (USD) (DiMasi, Grabowski, & Hansen, 2014) and requiring up
to a decade for development and regulatory approval (Pangalos et al.,
2007). This process has been reported to take even longer for pharma-
ceutical drugs targeting CNS disorders (Pangalos et al., 2007) since po-
tential CNS drugs possess higher attrition rates and safety concerns
compared to other therapeutic indications (Palmer & Alavijeh, 2012).
The CNS is one of the most difﬁcult areas to assess drug effects due to
the diverse array of potential secondary neuronal and non-neuronal tar-
gets (e.g., receptors, ion channels, enzymes and transporters) (Porsolt
et al., 2002; Wakeﬁeld, Pollard, Redfern, Hammond, & Valentin, 2002).
Furthermore, CNS drugs show the highest propensity for generating
adverse CNS effects (Easter et al., 2009).With the CNSdrugmarket fore-
casted to grow to $81.8 billion (USD) in 2015 (BCC Research, 2010), it
has become imperative that more comprehensive CNS safety assess-
ments are conducted early within drug development (Lindgren et al.,
2008; Valentin & Hammond, 2008).
Traditionally, as discussed above, early preclinical safety screens
have largely relied on behavioral assays (Irwin, 1968; Moser et al.,
1995) or in vivo electrophysiological assessments of neuronal activity
(e.g., EEG) (Authier et al., 2009, 2014; Kramer &Kinter, 2003). However,
the nature and use of thesemethods prevent a thorough understanding
of the mechanistic and molecular underpinnings contributing to ob-
served changes in neuronal network function. This ensemble or ‘black
box’ approach to pharmacodynamics can hinder the predictive powerof these assays. Non-electrophysiological in vitro techniques (Table 1)
may be used to investigate the molecular mechanism involved in a
drug response, but these techniques lack the overall speciﬁcity, sensitiv-
ity and time resolution attainable through electrophysiological means.
Thus it is unsurprising that several in vitro electrophysiological CNS
techniques are beginning to emerge as interesting tools in the world
of safety pharmacology.4.1. Receptor proﬁle safety screening
To increase preclinical predictability of adverse CNS effects, safety
pharmacology has begun to frontload in vitro pharmacological proﬁle
screening early in safety testing (Bowes et al., 2012). Pharmacological
proﬁling typically employs high-throughput radioligand binding assays
owing to low costs, low compound requirements and rapid turnaround
time (Armstrong et al., 2008; Easter et al., 2009). However, electrophys-
iological techniques are also suitable for in vitro pharmacological
proﬁling and have been effectively used in early phase cardiac ion
channel safety assessments (e.g., hERG, Nav1.5, Cav1.2, Kv4.3)
(Hancox, McPate, El Harchi, & Zhang, 2008; Moller & Witchel, 2011).
However, equivalent screens for the CNS has lagged, in part, due to a
limited consensus regarding appropriate neuronal targets. A recent re-
view of the strategies and methodologies used at four major pharma-
ceutical companies (Bowes et al., 2012) recommended 44 molecular
targets for in vitro pharmacological proﬁle screens of which a total of
21 were direct CNS targets (Table 2). These targets are included on a
recommended ‘minimal panel’ for safety testing which by no means
represents an exhaustive list since several additional CNS ion channel
targets could also be considered (Table 3). Since many of these targets
(particularly ion channels) are amenable to manual and automated
patch-clamp techniques, numerous drugs and their associated metabo-
lites can be screened on several potential targets within a relatively
short testing period (Terstappen et al., 2010). This approach can gener-
ate drug response proﬁles (e.g., IC50 values) and highlight altered chan-
nel responsiveness which, at a minimum, can be used to raise concerns
for future drug safety assessments (Wakeﬁeld et al., 2002). Further-
more, combining data obtained from receptor proﬁle safety screens
with other in vitro assays may indicate the need for speciﬁc CNS
Table 3
Additional CNS voltage- and ligand-gated ion channel considerations for receptor proﬁle safety assessments.
Class Ion channel type Common isoforms or
compositions
Voltage-gated calcium channels L-type Cav1.2; Cav1.3
P/Q-type Cav2.1
N-type Cav2.2
R-type Cav2.3
T-type Cav3.2
Voltage-gated potassium channels A-type Kv1.4
Delayed rectiﬁer Kv7.2/ Kv7.3; Kv7.3/ Kv7.5
Outward-rectifying Kv10.1; Kv10.2
Hyperpolization-gated, cyclic AMP-gated HCN1-2
Voltage-gated sodium channels Nav1.1
Nav1.2
Nav1.3
Nav1.5 (e.g., cerebellar isoform)
Nav1.6
Ligand-gated ion channels GABAAR α1β2/3γ2; α2β2/3γ2; α3β2/3γ2; α5β2/3γ2
NMDAR GluN1/GluN2A; GluN1/GluN2B
AMPAR GluA1/GluA2; GluA1/GluA4
Kainate receptor GluK2/GluK5
Calcium-activated potassium channels KCa2.2, KCa2.3
AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; GABAAR, γ-aminobutyric acid type A receptor; NMDAR, N-methyl-D-aspartate receptor.
54 M.V. Accardi et al. / Journal of Pharmacological and Toxicological Methods 81 (2016) 47–59in vivo studies, based on known CNS pharmacology (Wakeﬁeld et al.,
2002).
4.2. Liability testing
4.2.1. Seizure liability
Many pharmacological drugs have been associated with seizure lia-
bilities, a potentially life-threating ADR representing one of the most
frequent causes of injury or death in human clinical trials (Bass,
Kinter, & Williams, 2004). Estimates suggest that 6% of new-onset sei-
zures and up to 9% of status epilepticus cases are drug related (Chen,
Albertson, & Olson, 2015). Drugs associated with this liability span a
wide range of pharmacological classes and therapeutic areas (Table 4)
(Easter et al., 2009; Fonck et al., 2015; Kumlien & Lundberg, 2010). Un-
surprisingly, pharmaceutical drugs targeting CNS disorders show the
highest propensity for drug-induced seizures; however, other therapeu-
tic areas such as infectious, cardiovascular and the respiratory indica-
tions also present compounds with seizurogenic potential (Easter
et al., 2009). This is a particularly important concern for the pharmaceu-
tical industry underscoring the need for extensive safety testing
amongst all therapeutic classes. This is no better illustrated than with
Minaprine (Brantur, Cantor), an anti-depressive agent that was a
reversible inhibitor of monoamine oxidase-A (MAO-A), which was
withdrawn from the market in 1996 due to an increase in the clinical
incidence of convulsions (Fung et al., 2001).
Convulsions observed in pre-clinical studies are often the ﬁrst indi-
cation of the seizurogenic potential of a compound in development.
However, not all seizures express convulsive behavior (Chang &
Shinnar, 2011) requiring the use of EEG studies to pair clinical observa-
tions with electrical brain activity (Authier et al., 2009). Alternatively,
abnormal seizure-like activity can be easily induced in an in vitro brain
slice preparation by drugs known to induce seizures in vivo. The most
common brain region for in vitro brain slice seizure-liability assessment
is the hippocampus due, in part, to its (i) strong link to partial seizures
(Schwartzkroin, 1994), (ii) retention of many in situ cytoarchitectural
and microcircuitry properties (Lynch & Schubert, 1980), (iii) amenabil-
ity to various in vitro electrophysiological techniques (Dingledine, Dodd,
& Kelly, 1980) and (iv) its ability to bemaintained, in culture, for several
weeks (Gahwiler et al., 1997; Humpel, 2015). Additionally, unlike the
reductionist approach applied to recombinant expression systems, hip-
pocampal brain slices retain the impact of endogenous microcircuits
(between neurons, glia and capillaries) and signaling pathways
(e.g., ion channels, GPCRs, kinases, etc.) that make it more effective atpredicting unintended ADRs. In agreement with this, in vitro hippocam-
pal slices show strong concordance with in vivo exposure values of
various preclinical drug candidates and known seizurogenic agents
(Easter et al., 2009; Easter, Sharp, Valentin, & Pollard, 2007; Fonck
et al., 2015; Hablitz, 1984; Rostampour et al., 2002).
Seizurogenic activity is not restricted to the hippocampus with epi-
leptiform activity observed in the neocortex (Kennedy & Schuele,
2012), amygdala (Hudson et al., 1993), entorhinal cortex (Vismer,
Forcelli, Skopin, Gale, & Koubeissi, 2015), thalamocortical regions
(Timofeev & Steriade, 2004) and possibly cerebellum (Harvey et al.,
1996). Incidentally, seizure-like activity has also been recorded from
neocortical (Voss & Sleigh, 2010) and thalamocortical (Gibbs, Zhang,
Ahmed, & Coulter, 2002) brain slices. An interesting consideration
would also be the use of intact inter-regional brain models (e.g.,
cortico-hippocampal, hippocampal-entorhinal cortex), which maintain
neuronal connectivity between brain regions (Leutgeb, Frey, &
Behnisch, 2003; Luhmann & Kilb, 2012). This model is most effectively
used within cultured conditions (Luhmann & Kilb, 2012) and could be
useful in investigating the genesis and propagation of ictal discharges
between cortical, subcortical and limbic systems.4.2.2. Memory loss
Another use of hippocampal brain slice electrophysiological
methods involves preclinical assessments of drug-induced cognitive
deﬁcits and memory loss as memory loss related to pharmaceutical
use is a well-described phenomenon. Although not as widely used as
it is within seizure liability testing, hippocampal slice electrophysiology
has demonstrated great potential in studying learning and memory.
Learning and memory are strongly associated with hippocampal func-
tion (Jarrard, 1993; Squire, 1992) and are molecularly mediated by
both long-term potentiation (LTP) (Bliss & Collingridge, 1993; Bliss &
Lomo, 1973; Nicoll & Malenka, 1999) and long-term depression (LTD)
(Kemp & Bashir, 2001). LTP and LTD represent a long-lasting change
in synaptic strength that may result in a potentiation or depression of
synaptic function, respectively. These mechanisms have been exten-
sively studied, both in vitro and in vivo, within multiple preclinical spe-
cies (Fonck et al., 2015). For instance, electrophysiological experiments
in rodent hippocampal slices have shown that compounds known to
cause deﬁcits in human memory in vivo, such as benzodiazepines
(Tokuda, O'Dell, Izumi, & Zorumski, 2010) and glutamate receptor an-
tagonists (Parsons, Stofﬂer, & Danysz, 2007), have also led to dramatic
changes in the magnitude of LTP in vitro.
Table 4
Select drugs with known seizurogenic potential in humans.
Class Drug Relative seizure
provocation frequency
Other comments
Anesthetic Propofol Common Effects are well documented
Enﬂurane Rare grand ma1 seizure patterns
induced at concentrations of
3%–6%a
Antiarrhythmic Lignocaine Uncommon Also an anesthetic; convulsion may occur with N75 μg/kg/min and blood concentrations above 9 mg/Lb
Mexiletine Rare
Antibiotic Penicillins Common in high doses e.g., penicillin G; penicillin induced seizures seen between 9 and 180 mg/kgc; 89–303 mg/L required to cause
epileptiform activity in rat hippocampal slicesc.
Cephalosporins Common in high doses e.g., Cefazolin — shown to promote seizures at 100 mgd
Analgesic Tramadol Rare
Meperidine Rare High doses
Antihistamine Diphenhydramine Typical within withdrawal
Hydroxyzine Typical within withdrawal
Antipsychotic Chlorpromazine Rare Observed with doses b 1000 mg/daye; cause seizurogenic activity in guinea pig hippocampal slices between
50 and 200 ng/mlf
Clozapine Common N600 mg/day (4.4–14% risk of seizures)a some also observed b 300 mg/daye
Antidepressant Bupropion Rare
Minaprine Common Withdrawn from market
Maprotiline Uncommon Seizures associated with doses N 225 mg/dayg; Increased of 46% neuronal excitability in guinea pig
hippocampal slices at 600 ng/mlh
Antimigraine Sumatriptan Rare
Anxiolytic Alprazolam Rare Typical within withdrawal
Lorazepam Rare Typical within withdrawal
Anti-Parkinson Pergolide Rare Withdrawn from market
Bladder Oxybutynin Common Reduce bladder muscle spasms
Blood pressure Carvedilol Rare
Reserpine Rare May also be used to treat schizophrenia
Cancer Temozolomide Common
Vincristine Rare
Busulfan Uncommon Anticonvulsant therapy should accompany high doses
Gastrointestinal Ondansetron Rare May be used to anorexia
Dronabinol Rare High Doses
Immune Cyclosporine Common Elevated plasma levels (320 to 1590 ng/ml) associated with seizuresi; seizures induced in hippocampal
slice between 1000 and 10,000 ng/mlj
Neuroleptic Chlorprothiexene Common
Dementia Donepezil Rare
Rivastigmin Rare
Respiratory Theophylline Common Bronchodilator; shown to cause seizures as low as 10 to 20 mg/Lg; Convulsive dose (CD50) in a rat
hippocampal slice is 3 μMk
Skin care Isotretinoin Rare
a Modica, Tempelhoff, and White (1990).
b Zaccara, Muscas, and Messori (1990).
c Grondahl and Langmoen (1993).
d Wallace (1997).
e Pisani, Oteri, Costa, Di Raimondo, and Di Perri (2002).
f Oliver, Luchins, and Wyatt (1982).
g Franson et al. (1995).
h Luchins, Oliver, and Wyatt (1984).
i Wijdicks, Plevak, Wiesner, and Steers (1996).
j Wong and Yamada (2000).
k Ault et al. (1987).
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organotypic culture) study of LTP/LTD (Lein, Barnhart, & Pessah, 2011)
amenable to high throughput assessment (Kroker, Rosenbrock, & Rast,
2011). This is particularly important in the context of chronic exposure
of pharmaceutical, industrial and/or agricultural chemicals on cognitive
function (Altmann et al., 2002; Fonck et al., 2015; Sanders, Liu, Buchner,
& Tchounwou, 2009). For example, anticholinergic (Cai, Campbell,
Khan, Callahan, & Boustani, 2013), statins (Wagstaff, Mitton, Arvik, &
Doraiswamy, 2003) and antianxiety medication (e.g., benzodiazepines)
(Curran, 1986) have all been shown to alter cognitive function
in less than 60 days. In fact, a wide range of drug classes are known
to illicit adverse cognitive effects in some fashion (e.g., antiseizure,
antidepressant, narcotic painkillers, dopamine agonists, beta-blockers,
nonbenzodiazepine sedative-hypnotics and antihistamines) (Wood,
1984). Given this, the usefulness of an in vitro memory/cognitive
dysfunction assay within the safety pharmacology arena cannot be
overlooked.4.2.3. Other possible liability tests
As our understanding of the safety testing evolves to incorporate
an ever more sophisticated list of drug development liabilities, new
assays and/or improvements of older assays may begin to take hold.
For instance, drug-induced sleep disorders are a frequent concern
since numerous drug classes (e.g., antidepressants, antihistamines, anti-
psychotics and corticosteroids) have shown sleep disturbances. Accord-
ingly, it has been suggested that in vitro brain slice electrophysiology
may represent an important area for which in vitro screensmay develop
(Fonck et al., 2015). Nerve conduction velocity testing is often included
in non-clinical studies (Arezzo, Litwak, & Zotova, 2011; Zotova&Arezzo,
2013) and serves as a quantitative assessment of possible impairment of
impulse transmission in the central/peripheral sensory andmotor path-
ways. However, limited in vitro models have been qualiﬁed for early
screening of such effects. Sensory neuronal networks are also common-
ly used to assess potential pharmacological effects. For example, freshly
isolated dorsal root ganglia represent an application of in vitro
56 M.V. Accardi et al. / Journal of Pharmacological and Toxicological Methods 81 (2016) 47–59electrophysiology to drug development (Serrano et al., 2012; Serrano
et al., 2010); but there remains limited understanding of the transla-
tional value of such an assay.
4.3. Implementation of high-throughput techniques
Historically marred by low throughput and the requirement for
highly trained personal, manual in vitro electrophysiology methods
have seen slow and heterogeneous penetrance into the non-clinical
drug development landscape. Over the last decade, several automated
and semi-automated high-throughput platforms have addressed these
concerns by simplifying the patching procedure and increasing the
data acquisition capabilities of in vitro electrophysiology methods
(Dunlop et al., 2008; Fertig & Farre, 2010; Terstappen et al., 2010;
Wood et al., 2004). However, despite these advances, automated
patch-clamp platforms have seen slow application and endorsement
into the battery of safety pharmacologymethods available to determine
drug safety. In a recent market survey (HTStec Limited, 2014), 76% of
current automated platform users responded that high-throughput sys-
tems are principally employed for assay development with only a quar-
ter (25%) or half (55%) of the responders indicating use in GLP
compliant or non-compliant safety assessments, respectively (Comley,
2014). This is partly due to the fact that current high-throughput auto-
mated patching systems are more applicable to primary screening and
hits-to-leads (lead optimization) operations (Dunlop et al., 2008;
Fertig & Farre, 2010) than safety testing. However, other logistical and
economic factorsmay also be at play such as the cost of automated plat-
forms and their associated consumables (Comley, 2014; Dunlop et al.,
2008; Farre & Fertig, 2012). In fact, it was not until the development
of automated systems capable of performing 384 and 768 parallel
recordings that the cost per data point was actually below $1 (USD)
(Comley, 2014).
Another issue is thatmost of the existing high-throughput platforms
are designed to record from eithermammalian cell lines and/or Xenopus
oocytes (Dunlop et al., 2008; Wood et al., 2004). Thus, extrapolation of
data obtained from these tissue preparations to the in vivo condition,
where network connectivity is an undeniable inﬂuence, is quite
limited – hampering predictive power. Recent advancements with au-
tomated patch-clamp techniques have begun to address this concern
by expanding the high throughput capacity to preparationsmore appli-
cable to the in vivo condition. For instance, MEAs and semi-automated
in vitro hippocampal brain slice assays have been adapted for high-
throughput analysis (Dunlop et al., 2008). These systems are capable
of using mixed organotypic slice cultures or multiple acute brain slices
(up to eight brain slices) providing in vitro safety models with a neuro-
nal network perspective (Dunlop et al., 2008; Easter et al., 2007; Kroker
et al., 2011; Obien et al., 2014). MEAs, for example, provide the possibil-
ity of long-term culture enabling chronic seizurogenic compound expo-
sure; a useful technique for understanding how compounds that are
prone to development of drug-induced seizures in humans change epi-
leptiform activity over time. Furthermore, the automated patch clamp
technique has been recently developed for simultaneous in vivo intra-
cellular recordings from multiple neurons (Kodandaramaiah, Franzesi,
Chow, Boyden, & Forest, 2012). This technique enables a technician, or
robot, to rapidly obtain giga-seals on neurons of the same quality
achieved by that of a skilled electrophysiologist (Kodandaramaiah
et al., 2012). Although the full extent of the applicability of this tech-
nique is not yet been realized within safety pharmacology, its potential
in vivo applicability with in vitro-type data quality is quite promising.
5. Conclusions
High drug attrition rateswithin pharmaceutical development due to
adverse CNS effects (Arrowsmith & Miller, 2013; Fung et al., 2001;
Hamdam et al., 2013; Palmer & Alavijeh, 2012; Pangalos et al., 2007)
has led to the growing support for the requirement to perform morecomprehensive CNS safety testing prior to clinical studies (Lindgren
et al., 2008; Valentin & Hammond, 2008). Accordingly, CNS safety test-
ing has begun to be frontloadedwith in vitro assays (Bowes et al., 2012),
calling for the re-evaluation of themerits for implementing in vitro elec-
trophysiology testing early in this process. This rapid implementation
into early-phase safety pharmacology warrants a call to ensure that
these assays are met with a strict monitoring program from which it
can be determined whether their implementation is justiﬁed by their
predictive ability. In light of this, many recent studies have begun to
highlight the success of in vitro electrophysiological CNS safety assays
at reproducing in vitro–in vivo concordance with respect to certain pre-
clinical drug candidates (Easter et al., 2007, 2009; Fonck et al., 2015;
Kroker et al., 2011); demonstrating the translational potential of these
assays in safety pharmacology. However, more studies are required to
fully address and understand the nuances between in vitro–in vivo sys-
tems before full implementation within safety pharmacology can occur.
It should be noted that, like most areas of medical science, a single ap-
proachwill not be suitable to all programs. As such, in vitro electrophys-
iological methods should not be considered a replacement for in vivo
assessments particularly because it is impossible to address the pres-
ence of certain adverse CNS effects in vitro (e.g., delirium, confusion, hal-
lucination, depression, schizophrenic and/or paranoid reactions, etc.).
Instead, when paired with more traditional safety pharmacology
methods, in vitro electrophysiology provides screening assays from
which a greater understanding of preclinical drug liabilities can emerge.
In vitro electrophysiological methods represent an area with opportuni-
ties for reﬁnement as the ﬁeld solidiﬁes its foundation to support drug
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